Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
- Authors:
- Andrea Ritter
- Marc Hirschfeld
- Kai Berner
- Gerta Rücker
- Markus Jäger
- Daniela Weiss
- Markus Medl
- Claudia Nöthling
- Sandra Gassner
- Jasmin Asberger
- Thalia Erbes
-
Affiliations: Department of Obstetrics and Gynecology, Faculty of Medicine, Medical Center‑University of Freiburg, D‑79106 Freiburg, Germany, Institute of Medical Biometry and Statistics, Faculty of Medicine, Medical Center‑University of Freiburg, D‑79104 Freiburg, Germany - Published online on: November 25, 2019 https://doi.org/10.3892/ijo.2019.4920
- Pages: 47-68
-
Copyright: © Ritter et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
World Health Organization IAfRoC: Cancer Today. 2018, https://gco.iarc.fr/today/home. Accessed April 4, 2019. | |
|
DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar | |
|
Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI | |
|
Pérou CM, Sprlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sprlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar | |
|
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ and Panel Members: Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 20l5. Ann Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
American Cancer Society: Breast CancerFacts &Figures. 2017-2018, American Cancer Society; Atlanta, GA: 2017, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-stati-stics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf. Accessed April 02, 2019. | |
|
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al: Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 24:157–167. 2011. View Article : Google Scholar | |
|
Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB and Lannin DR: Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 95:e46142016. View Article : Google Scholar | |
|
Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, Axelrod D, Shapiro R and Schnabel F: Clinical characteristics in patients with triple negative breast cancer. Int J Breast Cancer. 2017:17961452017. View Article : Google Scholar : PubMed/NCBI | |
|
Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 9(Suppl 2): S73–S81. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Toft DJ and Cryns VL: Minireview: Basal-like breast cancer: From molecular profiles to targeted therapies. Mol Endocrinol. 25:199–211. 2011. View Article : Google Scholar : | |
|
Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P and Birnbaum D: How basal are triple-negative breast cancers? Int J Cancer. 123:236–240. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar | |
|
Mieog JS, van der Hage JA and van de Velde CJ: Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 94:1189–1200. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mieog JS, van der Hage JA and van de Velde CJ: Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. CD0050022007.PubMed/NCBI | |
|
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16:2672–2685. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, et al: Preoperative chemotherapy: Updates of National surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C and Duchateau L: Preoperative chemotherapy in primary operable breast cancer: Results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol. 19:4224–4237. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, Ferrari L, Bottini A, Bruzzi P and Sormani MP: Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: A meta-regression of 29 randomized prospective studies. J Clin Oncol. 32:3883–3891. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, et al: Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 144:153–162. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, et al: Impact of treatment characteristics on response of different breast cancer phenotypes: Pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 125:145–156. 2011. View Article : Google Scholar | |
|
von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, et al: Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 31:3623–3630. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Diagnosis and treatment of patients with primary and metastatic breast cancer. http://www.ago-online.de. Accessed April 2, 2019. | |
|
Marinovich ML, Houssami N, Macaskill P, von Minckwitz G, Blohmer JU and Irwig L: Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer. Int J Cancer. 136:2730–2737. 2015. View Article : Google Scholar | |
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar | |
|
Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, et al: Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 243:257–264. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sadeghi-Naini A, Sannachi L, Tadayyon H, Tran WT, Slodkowska E, Trudeau M, Gandhi S, Pritchard K, Kolios MC and Czarnota GJ: Chemotherapy-response monitoring of breast cancer patients using quantitative ultrasound-based Intra-tumour heterogeneities. Sci Rep. 7:103522017. View Article : Google Scholar : PubMed/NCBI | |
|
Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, et al: International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fifth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy 2013. J Natl Cancer Inst Monogr. 2015:90–96. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liedtke C, Mazouni C, Hess KR, Andrè F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, et al: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol. 16:56–63. 2005. View Article : Google Scholar | |
|
Hombach S and Kretz M: Non-coding RNAs: Classification, biology and functioning. Adv Exp Med Biol. 937:3–17. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Brosnan CA and Voinnet O: The long and the short of noncoding RNAs. Curr Opin Cell Biol. 21:416–425. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Anastasiadou E, Jacob LS and Slack FJ: Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018. View Article : Google Scholar | |
|
Izzotti A, Carozzo S, Pulliero A, Zhabayeva D, Ravetti JL and Bersimbaev R: Extracellular MicroRNA in liquid biopsy: Applicability in cancer diagnosis and prevention. Am J Cancer Res. 6:1461–1493. 2016.PubMed/NCBI | |
|
Qi P, Zhou XY and Du X: Circulating long non-coding RNAs in cancer: Current status and future perspectives. Mol Cancer. 15:392016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Cheng Y, Lu Q, Wei J, Yang H and Gu M: Detection of stably expressed piRNAs in human blood. Int J Clin Exp Med. 8:13353–13358. 2015.PubMed/NCBI | |
|
Fanale D, Castiglia M, Bazan V and Russo A: Involvement of Non-coding RNAs in Chemo- and radioresistance of colorectal cancer. Adv Exp Med Biol. 937:207–228. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Magee P, Shi L and Garofalo M: Role of microRNAs in chemo- resistance. Ann Transl Med. 3:3322015. | |
|
Wang YW, Zhang W and Ma R: Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data. Oncol Rep. 39:1003–1010. 2018.PubMed/NCBI | |
|
Malhotra A, Jain M, Prakash H, Vasquez KM and Jain A: The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer. Oncotarget. 8:110671–110684. 2017. View Article : Google Scholar | |
|
Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, et al: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 4:e61462009. View Article : Google Scholar : PubMed/NCBI | |
|
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of Early breast cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Busk PK: A tool for design of primers for microRNA-specific quantitative RT-qPCR. BMC Bioinformatics. 15:292014. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar | |
|
Torres A, Torres K, Wdowiak P, Paszkowski T and Maciejewski R: Selection and validation of endogenous controls for microRNA expression studies in endometrioid endometrial cancer tissues. Gynecol Oncol. 130:588–594. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bockmeyer CL, Säuberlich K, Wittig J, Eßer M, Roeder SS, Vester U, Hoyer PF, Agustian PA, Zeuschner P, Amann K, et al: Comparison of different normalization strategies for the analysis of glomerular microRNAs in IgA nephropathy. Sci Rep. 6:319922016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Jin Y, Wang L, Sun F, Yang X, Shi M, Zhan C, Shi Y and Wang Q: Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma. Med Oncol. 34:22017. View Article : Google Scholar | |
|
Masè M, Grasso M, Avogaro L, D'Amato E, Tessarolo F, Graffigna A, Denti MA and Ravelli F: Selection of reference genes is critical for miRNA expression analysis in human cardiac tissue. A focus on atrial fibrillation. Sci Rep. 7:411272017. View Article : Google Scholar : PubMed/NCBI | |
|
Pfaffl MW, Tichopad A, Prgomet C and Neuvians TP: Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper-Excel-based tool using pair-wise correlations. Biotechnol Lett. 26:509–515. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F and Vandesompele J: A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 10:R642009. View Article : Google Scholar : PubMed/NCBI | |
|
D'Haene B, Mestdagh P, Hellemans J and Vandesompele J: miRNA expression profiling: From reference genes to global mean normalization. Methods Mol Biol. 822:261–272. 2012. View Article : Google Scholar | |
|
Schwarzenbach H, da Silva AM, Calin G and Pantel K: Data Normalization strategies for MicroRNA quantification. Clin Chem. 61:1333–1342. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Erbes T, Hirschfeld M, Rücker G, Jaeger M, Boas J, Iborra S, Mayer S, Gitsch G and Stickeler E: Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer. 15:1932015. View Article : Google Scholar : PubMed/NCBI | |
|
Marabita F, de Candia P, Torri A, Tegnér J, Abrignani S and Rossi RL: Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform. 17:204–212. 2016. View Article : Google Scholar : | |
|
Song W, Zhang WH, Zhang H, Li Y, Zhang Y, Yin W and Yang Q: Validation of housekeeping genes for the normalization of RT-qPCR expression studies in oral squamous cell carcinoma cell line treated by 5 kinds of chemotherapy drugs. Cell Mol Biol (Noisy-le-Grand). 62:29–34. 2016. View Article : Google Scholar | |
|
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem. 150:76–85. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Schägger H and von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 166:368–379. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna: 2018 | |
|
Gao D, Qi X, Zhang X, Fang K, Guo Z and Li L: hsa_ circRNA_0006528 as a competing endogenous RNA promotes human breast cancer progression by sponging miR-75p and activating the MAPK/ERK signalling pathway. Mol Carcinog. 58:554–564. 2019. View Article : Google Scholar | |
|
Gao D, Zhang X, Liu B, Meng D, Fang K, Guo Z and Li L: Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics. 9:1175–1188. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Uhr K, Sieuwerts AM, de Weerd V, Smid M, Hammerl D, Foekens JA and Martens JWM: Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer. Sci Rep. 8:96572018. View Article : Google Scholar : | |
|
Garcia-Vazquez R, Ruiz-García E, Meneses García A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda A, Mal donado-Martínez H, Gonzalez-Barrios JA, Campos-Parra AD, Rodríguez Cuevas S, et al: A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol. 39:10104283177028992017. View Article : Google Scholar : PubMed/NCBI | |
|
Unger FT, Klasen HA, Tchartchian G, de Wilde RL and Witte I: DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer. 9:3592009. View Article : Google Scholar : PubMed/NCBI | |
|
Su WC, Chang SL, Chen TY, Chen JS and Tsao CJ: Comparison of in vitro growth-inhibitory activity of carboplatin and cisplatin on leukemic cells and hematopoietic progenitors: The myelosuppressive activity of carboplatin may be greater than its antileukemic effect. Jpn. J Clin Oncol. 30:562–567. 2000. | |
|
Kuittinen T, Rovio P, Staff S, Luukkaala T, Kallioniemi A, Grénman S, Laurila M and Maenpaa J: Paclitaxel, carboplatin and 1,25D3 inhibit proliferation of endometrial cancer cells in vitro. Anticancer Res. 37:6575–6581. 2017.PubMed/NCBI | |
|
He Q, Liang CH and Lippard SJ: Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA. 97:5768–5772. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Diehl JA, Zindy F and Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11:957–972. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Luo H, Zhang J, Dastvan F, Yanagawa B, Reidy MA, Zhang HM, Yang D, Wilson JE and McManus BM: Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol. 77:1–9. 2003. View Article : Google Scholar : | |
|
Fuller-Pace FV: DEAD box RNA helicase functions in cancer. RNA Biol. 10:121–132. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mazurek A, Luo W, Krasnitz A, Hicks J, Powers RS and Stillman B: DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. Cancer Discov. 2:812–825. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Huang J and Hu Z: RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics. 11:M111.0119322012. View Article : Google Scholar : | |
|
Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, Wardrop J, Gregory DJ, Lane DP, Perkins ND and Fuller-Pace FV: The DEAD box protein p68: A novel transcriptional coactivator of the p53 tumour suppressor. EMBO J. 24:543–553. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wortham NC, Ahamed E, Nicol SM, Thomas RS, Periyasamy M, Jiang J, Ochocka AM, Shousha S, Huson L, Bray SE, et al: The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer. Oncogene. 28:4053–4064. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shin S, Rossow KL, Grande JP and Janknecht R: Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res. 67:7572–7578. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jalal C, Uhlmann-Schiffler H and Stahl H: Redundant role of DEAD box proteins p68 (Ddx5) and p72/p82 (Ddx17) in ribosome biogenesis and cell proliferation. Nucleic Acids Res. 35:3590–3601. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Concepcion CP, Bonetti C and Ventura A: The microRNA-17-92family of microRNA clusters in development and disease. Cancer J. 18:262–267. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mogilyansky E and Rigoutsos I: The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 20:1603–1614. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, et al: MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 71:4443–4453. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, Filassi JR and Baracat EC: Triple-negative and luminal A breast tumors: Differential expression of miR-18a-5p, and miR-17-5p, and miR-20a-5p. Tumour Biol. 35:7733–7741. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hashim A, Rizzo F, Marchese G, Ravo M, Tarallo R, Nassa G, Giurato G, Santamaria G, Cordella A, Cantarella C and Weisz A: RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer. Oncotarget. 5:9901–9910. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Su F, Chen M, Li Y, Qi X, Xiao J, Li X, Liu X, Liang W, Zhang Y and Zhang J: Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. Hum Pathol. 64:44–52. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gu X, Xue JQ, Han SJ, Qian SY and Zhang WH: Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. Cancer Biomark. 16:395–403. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Khanbashi M, Caramuta S, Alajmi AM, Al-Haddabi I, Al-Riyami M, Lui WO and Al-Moundhri MS: Tissue and Serum miRNA profile in locally advanced breast cancer (LABC) in response to Neo-adjuvant chemotherapy (NAC) treatment. PLoS One. 11:e01520322016. View Article : Google Scholar : PubMed/NCBI | |
|
Edgar JR: Q&A: What are exosomes, exactly? BMC Biol. 14:462016. View Article : Google Scholar : | |
|
Ben-Dov IZ, Whalen VM, Goilav B, Max KE and Tuschl T: Cell and microvesicle urine microRNA deep sequencing profiles from healthy individuals: Observations with potential impact on biomarker studies. PLoS One. 11:e01472492016. View Article : Google Scholar : PubMed/NCBI | |
|
Mansoori B, Mohammadi A, Shirjang S, Baghbani E and Baradaran B: Micro RNA 34a and Let-7a expression in human breast cancers is associated with apoptotic expression genes. Asian Pac J Cancer Prev. 17:1887–1890. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu K, Zhang C, Li T, Ding Y, Tu T, Zhou F, Qi W, Chen H and Sun X: Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. Int J Oncol. 46:2526–2534. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Marques MM, Evangelista AF, Macedo T, Vieira RADC, Scapulatempo-Neto C, Reis RM, Carvalho AL and Silva IDCGD: Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer. Clinics (Sao Paulo). 73:e1842018. View Article : Google Scholar : | |
|
Huang SK, Luo Q, Peng H, Li J, Zhao M, Wang J, Gu YY, Li Y, Yuan P, Zhao GH and Huang CZ: A Panel of serum noncoding RNAs for the diagnosis and monitoring of response to therapy in patients with breast cancer. Med Sci Monit. 24:2476–2488. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Khalighfard S, Alizadeh AM, Irani S and Omranipour R: Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep. 8:179812018. View Article : Google Scholar : PubMed/NCBI | |
|
Mi Y, Liu F, Liang X, Liu S, Huang X, Sang M and Geng C: Tumor suppressor let-7a inhibits breast cancer cell proliferation, migration and invasion by targeting MAGE-A1. Neoplasma. 66:54–62. 2019. View Article : Google Scholar | |
|
Guo Q, Wen R, Shao B, Li Y, Jin X, Deng H, Wu J, Su F and Yu F: Combined Let-7a and H19 signature: A prognostic index of progression-free survival in primary breast cancer patients. J Breast Cancer. 21:142–149. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lehmann TP, Korski K, Gryczka R, Ibbs M, Thieleman A, Grodecka-Gazdecka S and Jagodzinski PP: Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer. Mol Med Rep. 12:4692–4702. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Thakur S, Grover RK, Gupta S, Yadav AK and Das BC: Identification of Specific miRNA signature in paired sera and tissue samples of Indian Women with Triple Negative breast cancer. PLoS One. 11:e01589462016. View Article : Google Scholar : PubMed/NCBI | |
|
Ahram M, Mustafa E, Zaza R, Abu Hammad S, Alhudhud M, Bawadi R and Zihlif M: Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells. Cell Biol Int. 41:1345–1355. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu CC, Chen YW, Chiou GY, Tsai LL, Huang PI, Chang CY, Tseng LM, Chiou SH, Yen SH, Chou MY, et al: MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol. 47:202–210. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu L, Zhang GF, Yu L, Wang HY, Jia XJ and Wang TJ: Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition. Sci Rep. 8:125222018. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao G, Wang X and Yu Y: CXCR4/Let-7a Axis regulates metastasis and chemoresistance of pancreatic cancer cells through targeting HMGA2. Cell Physiol Biochem. 43:840–851. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Serguienko A, Grad I, Wennerstrpm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O and Munthe E: Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA. Oncotarget. 6:2451–2465. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tsang WP and Kwok TT: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis. 13:1215–1222. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu J, Li S, Jia W, Deng H, Chen K, Zhu L, Yu F and Su F: Reduced let-7a is associated with chemoresistance in primary breast cancer. PLoS One. 10:e01336432015. View Article : Google Scholar : PubMed/NCBI | |
|
Bhutia YD, Hung SW, Krentz M, Patel D, Lovin D, Manoharan R, Thomson JM and Govindarajan R: Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: Role of LIN-28 and SET oncoprotein. PLoS One. 8:e534362013. View Article : Google Scholar : PubMed/NCBI | |
|
Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H and Katsaros D: MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol. 122:366–371. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y, Dong M, Teng R, Wu L, Fu P, et al: Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One. 7:e400082012. View Article : Google Scholar : PubMed/NCBI | |
|
Yin PT, Pongkulapa T, Cho HY, Han J, Pasquale NJ, Rabie H, Kim JH, Choi JW and Lee KB: Overcoming chemoresistance in cancer via combined MicroRNA therapeutics with anticancer drugs using multifunctional magnetic Core-shell nanoparticles. ACS Appl Mater Interfaces. 10:26954–26963. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Farré PL, Scalise GD, Duca RB, Dalton GN, Massillo C, Porretti J, Grana K, Gardner K, De Luca P and De Siervi A: CTBP1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis. Oncotarget. 9:13848–13858. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnaes GI, Perala M, et al: Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol. 14:R1262013. View Article : Google Scholar : PubMed/NCBI | |
|
Lv J, Xia K, Xu P, Sun E, Ma J, Gao S, Zhou Q, Zhang M, Wang F, Chen F, et al: miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother. 68:935–942. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Oztemur Islakoglu Y, Noyan S, Aydos A and Gur Dedeoglu B: Meta-microRNA biomarker signatures to classify breast cancer subtypes. OMICS. 22:709–716. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shan Y, Liu Y, Zhao L, Liu B, Li Y and Jia L: MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1. Int J Biochem Cell Biol. 90:48–58. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R and Slaby O: MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol. 7:1952012. View Article : Google Scholar : PubMed/NCBI | |
|
Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J and Wang Z: Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2:e752013. View Article : Google Scholar : PubMed/NCBI | |
|
Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao M, Cai J, Cai L, Jia J, Xie L, Zhu Y, Huang B, Jin D and Wang Z: Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res. 10:242017. View Article : Google Scholar : PubMed/NCBI | |
|
Block I, Burton M, Sprensen KP, Andersen L, Larsen MJ, Bak M, Cold S, Thomassen M, Tan Q and Kruse TA: Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer. Oncotarget. 9:9030–9042. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA and Martens JW: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA. 105:13021–13026. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gong C, Tan W, Chen K, You N, Zhu S, Liang G, Xie X, Li Q, Zeng Y, Ouyang N, et al: Prognostic value of a BCSC-associated MicroRNA signature in hormone receptor-positive HER2-negative breast cancer. EBioMedicine. 11:199–209. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W and Avril S: MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 162:511–521. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Ye P and Long X: Differential expression profiles of the transcriptome in breast cancer cell lines revealed by next generation sequencing. Cell Physiol Biochem. 44:804–816. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cui YX, Bradbury R, Flamini V, Wu B, Jordan N and Jiang WG: MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells. Br J Cancer. 117:89–101. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vera-Puente O, Rodriguez-Antolin C, Salgado-Figueroa A, Michalska P, Pernia O, Reid BM, Rosas R, Garcia-Guede A, SacristAn S, Jimenez J, et al: MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species. Transl Res. 200:1–17. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Filipits M, Nielsen TO, Rudas M, Greil R, Stoger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P and Gruber-Rossipal C: et al The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin. Cancer Res. 20:1298–1305. 2014. | |
|
Blume CJ, Hotz-Wagenblatt A, Hüllein J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, et al: p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 29:2015–2023. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu DZ, Chang B, Li XD, Zhang QH and Zou YH: MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1. Clin Transl Oncol. 19:1133–1140. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 12:247–256. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sporn JC, Katsuta E, Yan L and Takabe K: Expression of MicroRNA-9 is associated with overall survival in breast cancer patients. J Surg Res. 233:426–435. 2019. View Article : Google Scholar | |
|
Orangi E and Motovali-Bashi M: Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women. Gene. 687:272–279. 2019. View Article : Google Scholar | |
|
Naorem LD, Muthaiyan M and Venkatesan A: Identification of dysregulated miRNAs in triple negative breast cancer: A meta-analysis approach. J Cell Physiol. 234:11768–11779. 2019. View Article : Google Scholar | |
|
Kia V, Paryan M, Mortazavi Y, Biglari A and Mohammadi-Yeganeh S: Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells. J Cell Biochem. 120:5666–5676. 2019. View Article : Google Scholar | |
|
Jang MH, Kim HJ, Gwak JM, Chung YR and Park SY: Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol. 68:69–78. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng CW, Yu JC, Hsieh YH, Liao WL, Shieh JC, Yao CC, Lee HJ, Chen PM, Wu PE and Shen CY: Increased cellular levels of MicroRNA-9 and MicroRNA-221 correlate with cancer stemness and predict poor outcome in human breast cancer. Cell Physiol Biochem. 48:2205–2218. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, et al: miR-9 and miR-200 Regulate PDGFRp-mediated endothelial differentiation of tumor cells in Triple-negative breast cancer. Cancer Res. 76:5562–5572. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Pan Q, Wan X, Mao Y, Lu W, Xie X and Cheng X: Methylation-associated Has-miR-9 deregulation in pacli- taxel-resistant epithelial ovarian carcinoma. BMC Cancer. 15:5092015. View Article : Google Scholar | |
|
Pezuk JA, Miller TLA, Bevilacqua JLB, de Barros ACSD, de Andrade FEM, E Macedo LFA, Aguilar V, Claro ANM, Camargo AA, Galante PAF and Reis LFL: Measuring plasma levels of three microRNAs can improve the accuracy for identification of malignant breast lesions in women with BI-RADS 4 mammography. Oncotarget. 8:83940–83948. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS and Ditzel HJ: Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Mol Oncol. 8:874–883. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Zhao W, Wei P, Zuo W and Zhu S: Tumor suppressor p53 induces miR-15a processing to inhibit neuronal apoptosis inhibitory protein (NAIP) in the apoptotic response DNA damage in breast cancer cell. Am J Transl Res. 9:683–691. 2017.PubMed/NCBI | |
|
Patel N, Garikapati KR, Ramaiah MJ, Polavarapu KK, Bhadra U and Bhadra MP: miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1. Life Sci. 164:60–70. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hamdi K, Blancato J, Goerlitz D, Islam M, Neili B, Abidi A, Gat A, Ayed FB, Chivi S, Loffredo C, et al: Circulating Cell-free miRNA expression and its association with clinicopathologic features in inflammatory and non-inflammatory breast cancer. Asian Pac J Cancer Prev. 17:1801–1810. 2016. View Article : Google Scholar | |
|
Shinden Y, Akiyoshi S, Ueo H, Nambara S, Saito T, Komatsu H, Ueda M, Hirata H, Sakimura S, Uchi R, et al: Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res. 35:123–127. 2015.PubMed/NCBI | |
|
Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui W, Hao M and Qiu L: MicroRNA-15a/161 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget. 6:38270–38282. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Patel N, Garikapati KR, Makani VKK, Nair AD, Vangara N, Bhadra U and Pal Bhadra M: Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug. PLoS One. 13:e01902452018. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, et al: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 3:170292017. View Article : Google Scholar | |
|
Wang L, Zhang X, Sheng L, Qiu C and Luo R: LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer. Biosci Rep. 38:pii: BSR20180790. 2018. | |
|
Chu J, Zhu Y, Liu Y, Sun L, Lv X, Wu Y, Hu P, Su F, Gong C, Song E, et al: E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. Oncotarget. 6:31944–31957. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jurkovicova D, Smolkova B, Magyerkova M, Sestakova Z, Kajabova VH, Kulcsar L, Zmetakova I, Kalinkova L, Krivulcik T, Karaba M, et al: Down-regulation of traditional oncomiRs in plasma of breast cancer patients. Oncotarget. 8:77369–77384. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N, Zhang H, Liu Y, Su P, Zhang J, Wang X, Sun M, Chen B, Zhao W, Wang L, et al: SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death Differ. 26:843–859. 2019. View Article : Google Scholar | |
|
Yang F, Li Y, Xu L, Zhu Y, Gao H, Zhen L and Fang L: miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer. Onco Targets Ther. 10:543–550. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Li J, Dai L, Zheng J, Yi Z and Chen L: MiR-17-5p may serve as a novel predictor for breast cancer recurrence. Cancer Biomark. 22:721–726. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M and Iwase H: Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. Oncotarget. 8:69934–69944. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hesari A, Azizian M, Darabi H, Nesaei A, Hosseini SA, Salarinia R, Motaghi AA and Ghasemi F: Expression of circulating miR-17, miR-25, and miR-133 in breast cancer patients. J Cell Biochem. Nov 28–2018. View Article : Google Scholar : Epub ahead of print. | |
|
Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, et al: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun. 9:16142018. View Article : Google Scholar : PubMed/NCBI | |
|
Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, et al: Aberrant miRNAs expressed in HER-2 negative breast cancers patient. J Exp Cli. Cancer Res. 37:2572018. | |
|
Li J, Lai Y, Ma J, Liu Y, Bi J, Zhang L, Chen L, Yao C, Lv W, Chang G, et al: miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer. BMC Cancer. 17:7452017. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Wu B, Chen L, Ju Y, Li C and Meng S: Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5. Oncotarget. 8:88645–88657. 2017.PubMed/NCBI | |
|
Cui YH, Kim H, Lee M, Yi JM, Kim RK, Uddin N, Yoo KC, Kang JH, Choi MY, Cha HJ, et al: FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation. Oncogene. 37:5794–5809. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang ST, Liu LB, Li XM, Wang YF, Xie PJ, Li Q, Wang R, Wei Q, Kang YH, Meng R, et al: Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/p-catenin pathway. Neoplasma. 66:232–239. 2019. View Article : Google Scholar | |
|
Jia J, Zhan D, Li J, Li Z, Li H and Qian J: The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. J Cell Mol Med. 23:656–669. 2019. View Article : Google Scholar | |
|
Wu DM, Hong XW, Wang LL, Cui XF, Lu J, Chen GQ and Zheng YL: MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. Int J Biochem Cell Biol. 102:59–70. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fan B, Shen C, Wu M, Zhao J, Guo Q and Luo Y: miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. Medicine (Baltimore). 97:e120072018. View Article : Google Scholar | |
|
Huang FX, Chen HJ, Zheng FX, Gao ZY, Sun PF, Peng Q, Liu Y, Deng X, Huang YH, Zhao C and Miao LJ: LncRNA BLACAT1 is involved in chemoresistance of nonsmall cell lung cancer cells by regulating autophagy. Int J Oncol. 54:339–347. 2019. | |
|
Gu J, Wang D, Zhang J, Zhu Y, Li Y, Chen H, Shi M, Wang X, Shen B, Deng X, et al: GFRa2 prompts cell growth and chemo- resistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Cancer Lett. 380:434–441. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cioffi M, Trabulo SM, Sanchez-Ripoll Y, Miranda-Lorenzo I, Lonardo E, Dorado J, Reis Vieira C, Ramirez JC, Hidalgo M, Aicher A, et al: The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut. 64:1936–1948. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yan HJ, Liu WS, Sun WH, Wu J, Ji M, Wang Q, Zheng X, Jiang JT and Wu CP: miR-17-5p inhibitor enhances chemo- sensitivity to gemcitabine via upregulating Bim expression in pancreatic cancer cells. Dig Dis Sci. 57:3160–3167. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ao X: Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregula- tion of NCOA3. Cell Death Dis. 7:e24632016. View Article : Google Scholar | |
|
Liao XH, Xiang Y, Yu CX, Li JP, Li H and Nie Q: STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget. 8:15763–15774. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Yang SY, Wang J, Wang L and Han SY: Evidence for miR-s17-92 and miR-134 gene cluster regulation of ovarian cancer drug resistance. Eur Rev Med Pharmacol Sci. 20:2526–2531. 2016.PubMed/NCBI | |
|
Fang Y, Xu C and Fu Y: MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon). 22:122015. View Article : Google Scholar | |
|
Chatterjee A, Chattopadhyay D and Chakrabarti G: miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One. 9:e957162014. View Article : Google Scholar : PubMed/NCBI | |
|
Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves TN, Pfeffer LM, Ignatova T and Fan M: MicroRNA-18a inhibits hypoxia-inducible factor 1a activity and lung metastasis in basal breast cancers. Breast Cancer Res. 16:R782014. View Article : Google Scholar | |
|
Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, DeRoo LA, Sandler DP and Taylor JA: Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 15:R422013. View Article : Google Scholar : PubMed/NCBI | |
|
Shidfar A, Costa FF, Scholtens D, Bischof JM, Sullivan ME, Ivancic DZ, Vanin EF, Soares MB, Wang J and Khan SA: Expression of miR-18a and miR-210 in normal breast tissue as candidate biomarkers of breast cancer risk. Cancer Prev Res (Phila). 10:89–97. 2017. View Article : Google Scholar | |
|
Sha LY, Zhang Y, Wang W, Sui X, Liu SK, Wang T and Zhang H: MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci. 20:2201–2208. 2016.PubMed/NCBI | |
|
Xiao H, Liu Y, Liang P, Wang B, Tan H, Zhang Y, Gao X and Gao J: TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis. Cell Biosci. 8:232018. View Article : Google Scholar : PubMed/NCBI | |
|
Hummel R, Sie C, Watson DI, Wang T, Ansar A, Michael MZ, Van der Hoek M, Haier J and Hussey DJ: MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol. 20:14904–14912. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fan YX, Dai YZ, Wang XL, Ren YQ, Han JJ and Zhang H: MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 20:2194–2200. 2016.PubMed/NCBI | |
|
Zhu HY, Bai WD, Ye XM, Yang AG and Jia LT: Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochem Biophys Res Commun. 496:1308–1313. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Zhou Y, Xia T, Zhou X, Huang Z, Zhang H, Zhu W, Ding Q and Wang S: Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res Treat. 170:257–270. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Zhang J, Ma Z, Zhang F and Yu W: miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther. 11:4087–4095. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Zhao Y, He Y and Mao Y: miR-19b promotes breast cancer metastasis through targeting MYLIP and its related cell adhesion molecules. Oncotarget. 8:64330–64343. 2017.PubMed/NCBI | |
|
Liu M, Yang R, Urrehman U, Ye C, Yan X, Cui S, Hong Y, Gu Y, Liu Y, Zhao C, et al: MiR-19b suppresses PTPRG to promote breast tumorigenesis. Oncotarget. 7:64100–64108. 2016.PubMed/NCBI | |
|
Maleki E, Ghaedi K, Shahanipoor K and Karimi Kurdistani Z: Down-regulation of microRNA-19b in hormone receptor-posi- tive/HER2-negative breast cancer. APMI. S. 126:303–308. 2018. | |
|
Wu Q, Guo L, Jiang F, Li L, Li Z and Chen F: Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER-breast cancer cell lines. J Cell Mol Med. 19:2874–2887. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kurokawa K, Tanahashi T, Iima T, Yamamoto Y, Akaike Y, Nishida K, Masuda K, Kuwano Y, Murakami Y, Fukushima M and Rokutan K: Role of miR-19b and its target mRNAs in 5-fluo - rouracil resistance in colon cancer cells. J Gastroenterol. 47:883–895. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Thorne JL, Battaglia S, Baxter DE, Hayes JL, Hutchinson SA, Jana S, Millican-Slater RA, Smith L, Teske MC, Wastall LM and Hughes TA: MiR-19b non-canonical binding is directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in breast cancer. Biochim Biophys Acta Gene Regul Mech. 1861:996–1006. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang T, Ye L, Han Z, Liu Y, Yang Y, Peng Z and Fan J: miR-19b-3p promotes colon cancer proliferation and oxalipl- atin-based chemoresistance by targeting SMAD4: Validation by bioinformatics and experimental analyses. J Exp Clin Cancer Res. 36:1312017. View Article : Google Scholar | |
|
Jin J, Sun Z, Yang F, Tang L, Chen W and Guan X: miR-19b-3p inhibits breast cancer cell proliferation and reverses saraca- tinib-resistance by regulating PI3K/Akt pathway. Arch Biochem Biophys. 645:54–60. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai HP, Huang SF, Li CF, Chien HT and Chen SC: Differential microRNA expression in breast cancer with different onset age. PLoS One. 13:e01911952018. View Article : Google Scholar : PubMed/NCBI | |
|
Chernyy V, Pustylnyak V, Kozlov V and Gulyaeva L: Increased expression of miR-155 and miR-222 is associated with lymph node positive status. J Cancer. 9:135–140. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong DD, Lv J, Wei KL, Feng ZB, Chen JT, Liu KC, Chen G and Luo DZ: A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases. Oncol Rep. 37:3297–3304. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bahrami A, Aledavood A, Anvari K, Hassanian SM, Maftouh M, Yaghobzade A, Salarzaee O, ShahidSales S and Avan A: The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. J Cell Physiol. 233:774–786. 2018. View Article : Google Scholar | |
|
Zhu M, Wang X, Gu Y, Wang F, Li L and Qiu X: MEG3 overexpression inhibits the tumorigenesis of breast cancer by downregulating miR-21 through the PI3K/Akt pathway. Arch Biochem Biophys. 661:22–30. 2019. View Article : Google Scholar | |
|
Wang W, Yuan X, Xu A, Zhu X, Zhan Y, Wang S and Liu M: Human cancer cells suppress behaviors of endothelial progenitor cells through miR-21 targeting IL6R. Microvasc Res. 120:21–28. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han JG, Jiang YD, Zhang CH, Yang YM, Pang D, Song YN and Zhang GQ: A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res. 92:55–66. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Liang J, Xu J, Li X, Xing S, Li H, Liu W, Liu D, Xu J, Huang L and Du H: Identification and validation of circulating MicroRNA signatures for breast cancer early detection based on large scale tissue-derived data. J Breast Cancer. 21:363–370. 2018. View Article : Google Scholar | |
|
Hu X, Fan J, Duan B, Zhang H, He Y, Duan P and Li X: Single-molecule catalytic hairpin assembly for rapid and direct quantification of circulating miRNA biomarkers. Anal Chim. Acta. 1042:109–115. 2018. | |
|
Fan T, Mao Y, Sun Q, Liu F, Lin JS, Liu Y, Cui J and Jiang Y: Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection. Cancer Sci. 109:2897–2906. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ: Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 18:902016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Ji S, Shao G, Zhang J, Zhao K, Wang Z and Wu A: Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clin Transl Oncol. 20:906–911. 2018. View Article : Google Scholar | |
|
Adhami M, Haghdoost AA, Sadeghi B and Malekpour Afshar R: Candidate miRNAs in human breast cancer biomark ers: A systematic review. Breast Cancer. 25:198–205. 2018. View Article : Google Scholar | |
|
Petrovic N, Sami A, Martinovic J, Zaric M, Nakashidze I, Lukic S and Jovanovic-Cupic S: TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. Pathol Res Pract. 213:1264–1270. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jinling W, Sijing S, Jie Z and Guinian W: Prognostic value of circulating microRNA-21 for breast cancer: A systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 45:1–6. 2017. View Article : Google Scholar | |
|
Papadaki C, Stratigos M, Markakis G, Spiliotaki M, Mastrostamatis G, Nikolaou C, Mavroudis D and Agelaki S: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 20:722018. View Article : Google Scholar : PubMed/NCBI | |
|
Huo D, Clayton WM, Yoshimatsu TF, Chen J and Olopade OI: Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 7:55231–55248. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shin VY, Siu JM, Cheuk I, Ng EK and Kwong A: Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 112:1751–1759. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fang H, Xie J, Zhang M, Zhao Z, Wan Y and Yao Y: miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res. 9:953–961. 2017.PubMed/NCBI | |
|
Dong G, Liang X, Wang D, Gao H, Wang L, Wang L, Liu J and Du Z: High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 31:572014. View Article : Google Scholar : PubMed/NCBI | |
|
Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Imamura T, Kiuchi J, Konishi H, Shiozaki A, et al: Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma. Am J Cancer Res. 6:1511–1523. 2016.PubMed/NCBI | |
|
Campayo M, Navarro A, Benitez JC, Santasusagna S, Ferrer C, Monzo M and Cirera L: miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer. PLoS One. 13:e02065422018. View Article : Google Scholar : PubMed/NCBI | |
|
Gaudelot K, Gibier JB, Pottier N, Hemon B, Van Seuningen I, Glowacki F, Leroy X, Cauffiez C, Gnemmi V, Aubert S and Perrais M: Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol. 39:10104283177073722017. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Tu HB, Wu L, Liu M and Jiang GN: MicroRNA-21 regulates non-small cell lung cancer cell invasion and chemo-sensitivity through SMAD7. Cell Physiol Biochem. 38:2152–2162. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Szejniuk WM, Robles AI, McCulloch T, Falkmer UGI and Roe OD: Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art. Pharmacogenomics J. 19:5–14. 2019. View Article : Google Scholar | |
|
Feng Y, Zou W, Hu C, Li G, Zhou S, He Y, Ma F, Deng C and Sun L: Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys. 623-624:20–30. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chan JK, Blansit K, Kiet T, Sherman A, Wong G, Earle C and Bourguignon LY: The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol. 132:739–744. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pink RC, Samuel P, Massa D, Caley DP, Brooks SA and Carter DR: The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 137:143–151. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dai X, Fang M, Li S, Yan Y, Zhong Y and Du B: miR-21 is involved in transforming growth factor |31-induced chemoresis- tance and invasion by targeting PTEN in breast cancer. Oncol Lett. 14:6929–6936. 2017.PubMed/NCBI | |
|
Bose RJC, Uday Kumar S, Zeng Y, Afjei R, Robinson E, Lau K, Bermudez A, Habte F, Pitteri SJ, Sinclair R, et al: Tumor cell-derived extracellular vesicle-coated nanocarriers: An efficient theranostic platform for the cancer-specific delivery of Anti-miR-21 and imaging agents. ACS Nano. 12:10817–10832. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Q, Zeng H, Ye P, Shi Y, Guo J and Long X: Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells. Anticancer Drugs. 29:539–548. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu ZH, Tao ZH, Zhang J, Li T, Ni C, Xie J, Zhang JF and Hu XC: MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumour Biol. 37:7245–7254. 2016. View Article : Google Scholar | |
|
Dhayat SA, Mardin WA, Seggewifi J, Strose AJ, Matuszcak C, Hummel R, Senninger N, Mees ST and Haier J: MicroRNA profiling implies new markers of gemcitabine chemoresistance in mutant p53 pancreatic ductal adenocarcinoma. PLoS One. 10:e01437552015. View Article : Google Scholar : PubMed/NCBI | |
|
Dong J, Zhao YP, Zhou L, Zhang TP and Chen G: Bcl-2 upregu- lation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res. 42:8–14. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kopczynska E: Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel. Contemp Oncol (Pozn). 19:423–427. 2015. | |
|
Haghnavaz N, Asghari F, Komi Ali Elieh D, Shanehbandi D, Baradaran B and Kazemi T: HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines. Artif Cells Nanomed Biotechnol. 46:518–523. 2018. View Article : Google Scholar | |
|
Du G, Cao D and Meng L: miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells. Mol Med Rep. 15:2713–2719. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jin B, Liu Y and Wang H: Antagonism of miRNA-21 sensitizes human gastric cancer cells to paclitaxel. Cell Biochem Biophys. 72:275–282. 2015. View Article : Google Scholar | |
|
Mei M, Ren Y, Zhou X, Yuan XB, Han L, Wang GX, Jia Z, Pu PY, Kang CS and Yao Z: Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat. 9:77–86. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Naro Y, Ankenbruck N, Thomas M, Tivon Y, Connelly CM, Gardner L and Deiters A: Small molecule inhibition of MicroRNA miR-21 rescues chemosensitivity of renal-cell carcinoma to topotecan. J Med Chem. 61:5900–5909. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, et al: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nat Commun. 9:47182018. View Article : Google Scholar : PubMed/NCBI | |
|
Decker JT, Hall MS, Blaisdell RB, Schwark K, Jeruss JS and Shea LD: Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2+ breast cancer. Biotechnol Bioeng. 115:2613–2623. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bahreyni A, Alibolandi M, Ramezani M, Sarafan Sadeghi A, Abnous K and Taghdisi SM: A novel MUC1 aptamer-modified PLGA-epirubicin-PpAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo. Colloids Surf B Biointerfaces. 175:231–238. 2018. View Article : Google Scholar | |
|
Vandghanooni S, Eskandani M, Barar J and Omidi Y: AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells. Nanomedicine (Lond). 13:2729–2758. 2018. View Article : Google Scholar | |
|
Wang W, Huang S, Yuan J, Xu X, Li H, Lv Z, Yu W, Duan S and Hu Y: Reverse multidrug resistance in human HepG2/ADR by Anti-miR-21 combined with hyperthermia mediated by functionalized gold nanocages. Mol Pharm. 15:3767–3776. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J, Zhao Q, Zhang W, Zhang Z, Gao J, Zhang C, Li Y and Tian Y: A novel panel of microRNAs provides a sensitive and specific tool for the diagnosis of breast cancer. Mol Med Rep. 10:785–791. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang K, Wang YW, Wang YY, Song Y, Zhu J, Si PC and Ma R: Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. Gene. 619:10–20. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabieres C, Lecellier CH, Bachelier R, Allioli N, Hong SS, et al: MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 78:5259–5273. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ni Q, Stevic I, Pan C, Muller V, Oliviera-Ferrer L, Pantel K and Schwarzenbach H: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Sci Rep. 8:129742018. View Article : Google Scholar : PubMed/NCBI | |
|
Xi Z, Si J and Nan J: LncRNA MALAT1 potentiates autophagyassociated cisplatin resistance by regulating the microRNA30b/autophagyrelated gene 5 axis in gastric cancer. Int J Oncol. 54:239–248. 2019. | |
|
Chen JC, Su YH, Chiu CF, Chang YW, Yu YH, Tseng CF, Chen HA and Su JL: Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells. Ann Surg Oncol. 21(Suppl 4): S555–S563. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tormo E, Adam-Artigues A, Ballester S, Pineda B, Zazo S, Gonzalez-Alonso P, Albanell J, Rovira A, Rojo F, Lluch A and Eroles P: The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci Rep. 7:413092017. View Article : Google Scholar : PubMed/NCBI | |
|
Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang F and Zhang SC: miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chin Med J (Engl). 126:4435–4439. 2013. | |
|
Amini S, Abak A, Estiar MA, Montazeri V, Abhari A and Sakhinia E: Expression Analysis of MicroRNA-222 in breast cancer. Clin Lab. 64:491–496. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zong Y, Zhang Y, Sun X, Xu T, Cheng X and Qin Y: miR-221/222 promote tumor growth and suppress apoptosis by targeting lncRNA GAS5 in breast cancer. Biosci Rep. 39:pii: BSR20181859. 2019. View Article : Google Scholar : | |
|
Hoppe R, Fan P, Buttner F, Winter S, Tyagi AK, Cunliffe H, Jordan VC and Brauch H: Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget. 7:71235–71254. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Han SH, Kim HJ, Gwak JM, Kim M, Chung YR and Park SY: MicroRNA-222 expression as a predictive marker for tumor progression in hormone receptor-positive breast cancer. J Breast Cancer. 20:35–44. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim C, Go EJ and Kim A: Recurrence prediction using microRNA expression in hormone receptor positive breast cancer during tamoxifen treatment. Biomarkers. 23:804–811. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu W, Liu M, Fan Y, Ma F, Xu N and Xu B: Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. Cancer Med. 7:4420–4433. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Lu P, Wang DD, Yang SJ, Wu Y, Shen HY, Zhong SL, Zhao JH and Tang JH: The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues. Gene. 595:221–226. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Chen Z, Huang J, Chen F, Ye W, Ding G and Wang X: Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling. Oncol Lett. 15:3017–3023. 2018.PubMed/NCBI | |
|
Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC, et al: miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules. 19:7122–7137. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Ren Y, Tang H, Wang W, He Q, Sun J, Zhou X and Wang A: Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential. Oncotarget. 6:44538–44550. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shen H, Wang D, Li L, Yang S, Chen X, Zhou S, Zhong S, Zhao J and Tang J: MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene. 596:110–118. 2017. View Article : Google Scholar | |
|
Wang DD, Yang SJ, Chen X, Shen HY, Luo LJ, Zhang XH, Zhong SL, Zhao JH and Tang JH: miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27(kip1) pathway. Tumour Biol. 37:15315–15324. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP: MicroRNA- 221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 30:1082–1097. 2011. View Article : Google Scholar | |
|
Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng L, Ding L, Zhang Y, Zhang L, Zhang L, et al: Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. Mol Cancer. 16:1322017. View Article : Google Scholar : PubMed/NCBI | |
|
Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K, Isenalumhe LL, Greco SJ, Ayer S, Bryan M, et al: Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 76:5832–5844. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ding J, Xu Z, Zhang Y, Tan C, Hu W, Wang M, Xu Y and Tang J: Exosome-mediated miR-222 transferring: An insight into NF-kappaB-mediated breast cancer metastasis. Exp Cell Res. 369:129–138. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gan R, Yang Y, Yang X, Zhao L, Lu J and Meng QH: Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther. 21:290–296. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vishnubalaji R, Hamam R, Yue S, Al-Obeed O, Kassem M, Liu FF, Aldahmash A and Alajez NM: MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1. Oncotarget. 7:35789–35802. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, et al: miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer. 109:502–511. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Zeringer E, Barta T, Schageman J, Cheng A and Vlassov AV: Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Philos Trans R Soc Lond B Biol Sci. 369:pii: 201305022014. View Article : Google Scholar |
